News
BMS is exiting the first U.S.-China pharmaceutical joint venture. Kalexo Bio and Ollin Biosciences have launched with big ...
Zacks Investment Research on MSN
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
Bristol Myers (BMY) is looking to boost its bottom-line growth as generic competition for legacy drugs (Revlimid, Pomalyst, ...
Zacks Investment Research on MSN
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
Bristol Myers Squibb (BMY) closed the most recent trading day at $45.60, moving -1.19% from the previous trading session.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback